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Introduction
Long acting reversible contraception (LARC) methods consist of the intrauterine device (IUD) and subdermal
implant. These birth control methods provide highly effective contraception that last from 3-10 years. The IUD comes in
both medicated (levonorgestrel-containing) and copper-containing form while the implant is inserted sub-dermally in the
upper arm under local anesthesia and releases a small continuous amount of the etonogestrel. Despite high efficacy,
LARC remains underutilized, with only 8.5% of contraceptive-using American women reporting its use (Finer 2012) .
The relationship between low LARC use and unintended pregnancy is documented (Secura 2013, Blumenthal 2013,
Blumenthal 2011). In the United States, more than half of all pregnancies are unintended, with an estimated annual direct
cost of $4.6 billion (Trussell 2013).
There are two well-accepted methods of LARC initiation – immediate postpartum and interval insertion. In
“immediate insertion,” LARC are placed within 72 hours of delivery, prior to hospital discharge. In contrast, “interval
insertion” encompasses delayed insertion at 4-8 weeks postpartum as well as LARC initiation that is not related to
pregnancy. Although immediate postpartum LARC initiation has been commonly practiced in other parts of the world for
the last three decades (Grimes 2010), only a few centers in the US offer this service.
The American College of Obstetricians and Gynecologists (ACOG) recommends the use of LARC in the
immediate postpartum period to aid in reducing unintended pregnancy rates and rapid repeat pregnancies (ACOG 2009,
2011). In the state of New Mexico, about 56% of pregnancies were unintended, with 58% ending in live births (NM
PRAMS 2008). Data from the University of New Mexico Hospital (UNMH) in 2002 show that about 12% of postpartum
women chose delayed LARC as their method of birth control. At best, only 60% of these women actually had a LARC
placed (Ogburn 2005). More recent data from 2006-2011 indicate an increasing number of women who plan to use birth
control after delivery, with preference for the implant and the IUD (Singh 2014).
Previous economic analysis of contraceptive methods show that, overall, LARC use leads to cost savings and
quality adjusted life years compared to methods which require patient adherence such as oral contraceptive pills
(Sonnenberg 2004, Secura 2013). Although previous research studies have been published regarding the cost
effectiveness of LARC use in general, no cost-effective or cost utility study have directly analyzed immediate postpartum
versus interval LARC use in the US.
Specific aims
Our long-term goal is to increase the practice and uptake of highly effective contraceptive methods in the US.
The overall objective of this application is to perform economic analyses of the two timing strategies of LARC initiation.
Cost effectiveness and cost utility analyses are methods for full economic evaluation that, combined, make use of the
decision analytic models in order to report costs with each unintended pregnancy that is prevented and costs with each
quality-adjusted life year (QALY) gained for any treatment or intervention (Gold MR 1996). The central hypothesis is
that immediate postpartum LARC insertion is more cost-effective than interval initiation. To test our central hypothesis

and attain the objective of this application, we plan to pursue the following three specific aims using the societal
perspective:
1. Cost utility analysis (CUA): Perform an incremental cost utility analysis (cost per QALY gained) of immediate
postpartum LARC initiation compared with interval insertion through the creation of a decision analytic model.
2. Cost effectiveness analysis (CEA): Determine the incremental cost per unintended pregnancy that is prevented
when LARC is initiated in the immediate postpartum period versus interval insertion.
3. Validate the model by conducting sensitivity analyses, using variables that may affect cost effectiveness and cost
utility results.
Based on a review of the literature, our working hypothesis is that immediate LARC initiation, through an
increase in patient compliance, will lead to a decrease in unintended pregnancy rates with its associated direct and indirect
costs, and to an increase in quality-adjusted life years. Additionally, we hypothesize that these results are robust across
varied time horizons, payer systems, and a wide range of probabilities and costs.
Replicable search strategy
In order to begin to achieve our aims, I conducted an extensive literature search on published economic
evaluations on the IUD and contraceptive implant. Through the PubMed database, I performed separate searches during
August 2014 for the IUD and during September 2014 for the sub-dermal implant. I considered all publications, whether
they conducted the analysis specifically on LARC or in combination with other birth control methods. I did not apply any
date and time restrictions since I wanted to capture all economic evaluations that have been completed in the past. Apart
from gaining information on what methods have been done, I also wanted to ensure comparability of my unit of reporting
with what was published.
Economic evaluations - Intrauterine Device (IUD)
Search # 1: On opening the MESH database at http://www.ncbi.nlm.nih.gov/mesh, I entered “Intrauterine device”
in the search bar. I then selected the first definition of “Intrauterine Devices” (which includes both medicated and copper
IUDs). I selected the subheading “economics” and did not restrict to MeSH Major Topic. I added it to the search builder
and searched PubMed.
Search #2: Returning to the Mesh Database, I entered “Intrauterine devices” in the search bar. I clicked on the
same definition and did not select any subheading. I added the term to the search builder and then entered “Economics” in
the search bar. Economics is defined as “the science of utilization, distribution, and consumption of services and
materials.” (Under the Health Care Category, economics encompassed costs and costs analysis). I selected on the
definition and did not select Restrict MeSH Major Topic. I added the term to the search builder and searched PubMed.
Next, I went to the Advanced Search Page. On the advanced search builder, I selected All Fields and added Search
#1. I proceeded to the second line and again, selected All Fields and clicked on Search #2. I chose the Boolean term OR
and hit Search. I filtered the results to Human and English. This search provided a total of one hundred eighty two (182)
articles on the IUD and Economics.
Search (("Intrauterine Devices/economics"[Mesh] AND Humans[Mesh] AND
English[lang])) OR (("Intrauterine Devices"[Mesh]) AND "Economics"[Mesh] AND
Humans[Mesh] AND English[lang]) Filters: Humans; English

182

22

I reviewed the title and abstract (when available) of each of the articles and selected relevant publications based
on the following inclusion and exclusion criteria.

Inclusion criteria: I considered all articles, including reviews and comparative observational studies, describing
any type of economic evaluations of IUDs. Partial economic evaluations include cost descriptions, cost analysis, and costoutcome descriptions, while CUAs, CEAs and cost-benefit analyses are considered full evaluations (Drummond 2005). I
considered the publication as long as the IUD (both medicated and copper containing) was analyzed, whether alone or in
combination with other contraceptive methods.
Exclusion criteria: I excluded articles from the search when it meets any of the following criteria:
1. Articles on IUD costs for non-contraceptive use (e.g. IUD use for heavy or dysfunctional menstrual bleeding)
2. Articles on IUD insertion costs post abortion
3. Articles on IUD costs for emergency contraceptive use
4. Articles on provider attitudes and practices on IUD insertion
5. Articles on IUD clinical risks and benefits alone, with no regard to costs
6. Articles on IUD cost marketing and other economic aspects such as patient incentives
6. Letters and editorials regarding IUD use
7. Reviews on the history and evolution of the IUD
Applying the inclusion and exclusion criteria yielded a total of twenty two (22) relevant articles (see Appendix A).
Economic evaluations - Sub-dermal contraceptive implant
I used the same search technique with regards to the contraceptive sub-dermal implant. Since the implant was
FDA approved only in the mid 1990’s (compared to the IUD which has been available since the 1970’s), as expected,
there is a significantly less number of published economic evaluations. Again, I did not apply any date or time restrictions
to the search.
Search # 1: Opening the MESH database at http://www.ncbi.nlm.nih.gov/mesh, I entered “Etonogestrel” in the
search bar. The heading will be mapped to Desogestrel. I clicked on “Desogestrel” and selected the subheading
“economics”. I did not restrict to MeSH Major Topic. I added the terms to the search builder and searched PubMed.
Search #2: Returning to the Mesh Database, I entered “Desogestrel” in the search bar. I selected the same
definition and did not select any subheading. I added the term to the search builder and then entered “Economics” in the
search bar. As above, “Economics” is defined as “the science of utilization, distribution, and consumption of services and
materials.” (Under the Health Care Category, economics encompasses costs and costs analysis). I clicked on the definition
and did not select any subheading. I did not select Restrict MeSH Major Topic and added the term to the search builder. I
then searched PubMed.
I navigated to the Advanced Search Page, and on the advanced search builder, I selected All Fields. I added
Search #1. I proceeded to the second line, selected All Fields and added Search #2. I chose the Boolean term OR and
clicked Search. I applied filters on Human and English. This search provided a total of thirteen (13) articles on the
contraceptive implant and Economics.
Search (("Desogestrel/economics"[Mesh] AND Humans[Mesh] AND
English[lang])) OR (("Desogestrel"[Mesh]) AND "Economics"[Mesh] AND
Humans[Mesh] AND English[lang]) Filters: Humans; English

13

7

6

Inclusion criteria: I included all economic evaluations on the sub-dermal contraceptive implant whether partial or
full.
Exclusion criteria: The following exclusion criteria were applied while reviewing the search results:
1. Articles on Implant for non-contraceptive use
2. Articles on Implant insertion post abortion

Again, I did not restrict articles based on study type, country and date of publication. Application of the inclusion
and exclusion criteria narrowed down the articles to seven (7). An overlap of one (1) article with the search strategy on the
IUD described above was also noted. This remained in the IUD literature search and was eliminated as a duplicate here.
This gave us a total of six (6) additional articles (see Appendix B).
Evaluation of References
My search strategy yielded a total of twenty nine (28) relevant journals/articles, 22 regarding the IUD and six on
the implant. I reviewed the references of each article, and retrieved their abstracts as appropriate. Using this meticulous
method, I was able to look up an additional twenty two (22) articles on the economic evaluation of the IUD (see Appendix
A). Serendipitously, I came across three articles on the IUD that were published in 2014 that have not been cited by any
article or even included in the original search results (see Appendix A: Trussell et al. 2014, Trussell et al 2014 and Frost
et al. 2014).
Summary
In summary, I searched the PubMed database to come up with relevant articles on the economic evaluation of the
IUD and contraceptive implant. Combined, I was able to find twenty eight (28) relevant journals and articles describing
partial or full economic evaluations, as defined by Drummond in 2005. I used the MeSH term intrauterine devices, to
pertain to both types of IUDs and the term desogestrel, which is the parent compound of the active ingredient of the
implant. I combined them with the term economics, which encompasses cost and cost analysis under the heading of health
economics. This technique, together with a very detailed and diligent search of the references, yielded an additional
twenty two (22) relevant journal articles. All in all, I was able to come up with a total of fifty (50) publications on the
economic evaluations of LARC.
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